Journal of Current and Advance Medical Research
January 2024, Vol. 11, No. 1, pp. 50-55
http://www.banglajol.info/index.php/JCAMR
ISSN (Print) 2313-447X
ISSN (Online) 2413-323X
NLM Catalog ID 101673828
DOI: https://doi.org/10.3329/jcamr.v11i1.77524

CASE REPORT

Exploring the Relationship Between Opioid Use Disorder and Major Depressive Disorder: A Case Study from Kentucky, United States

Md. Rakibul Hasan

Graduate Research Assistant (Biomedical Science, NIH) and PhD Student, Department of Health Promotion & Behavioural Sciences, School of Public Health and Information Sciences, University of Louisville, United States

Abstract

This case study explores the intricate and interconnected problems of drug usage and mental health in Kentucky, a state that has been greatly affected by the opioid epidemic and the high rate of mental illness. The study draws attention to the many difficulties that people with multiple diagnoses encounter, including stigma, difficulty obtaining integrated treatment, and the need for extensive support networks. Through a detailed case study of a 35-year-old male patient from Louisville, Kentucky—diagnosed with severe depressive disorder and opioid use disorder—this paper underscores the importance of integrated therapeutic approaches. As the case study was based on anonymized hospital records with no direct patient involvement or identifiable personal information, the Institutional Review Board (IRB) waived the requirement for ethical approval, and informed consent was not necessary. By combining medication-assisted treatment (MAT), cognitive-behavioral therapy (CBT), and community support, the patient's journey from numerous unsuccessful rehabilitation endeavors to significant progress is meticulously documented. In treating drug use and mental health difficulties, the case study demonstrates the efficacy of creative alternatives including peer support groups, telemedicine services, and community-based therapies. To improve outcomes for people with dual diagnoses throughout the United States, the paper ends with suggestions for expanding integrated care models and a discussion of the wider implications for public health policy. [*Journal of Current and Advance Medical Research, January 2024;11(1):50-55*]

Keywords: Opioid use disorder; depression; MDD; cognitive function, case study, United States

Correspondence: Dr. Md. Rakibul Hasan, *MBBS (DU), MPH (Cambridge, UK), Diploma in Neuroscience (UK), MCGP (BD), CCT in Emergency Medicine (University of Glasgow, Scotland), PGT in Healthcare (NHS London);* Graduate Research Assistant (Biomedical Science, NIH) and PhD Student, Dept. of Health Promotion & Behavioural Sciences, University of Louisville, 2301 S 3rd St, Louisville, KY 40292, United States; Former Healthcare Professional, Cambridge University Hospitals, NHS Foundation Trust, UK; Former Teaching Assistant, Cambridge Regional College, UK; **Email:** mdrakibul.hasan@louisville.edu; drmdrakibul@gmail.com; **ORCID:** https://orcid.org/0000-0002-9152-8753

Introduction

Opioid use disorder (OUD) and major depressive disorder (MDD) are substantial public health concerns, particularly in Kentucky. Opioids, which are also referred to as narcotics, encompass both prescription pain relievers, such as hydrocodone and oxycodone, and illicit substances, such as heroin[1]. These substances function by binding to opioid receptors in the brain, thereby reducing the perception of pain and generating euphoria. However, this can result in addiction and misuse[2]. Opioids are classified into three primary categories: natural like codeine, morphine, semi-synthetic like

hydrocodone, oxycodone and synthetic like methadone, fentanyl[3].

Major depressive disorder (MDD), also referred to as clinical depression, is a mental health condition that is widespread and is defined by a protracted period of profound sadness and a clear lack of interest in activities that were previously enjoyable[4]. Many aspects of an individual's life are significantly affected by this disorder, such as their emotional responses, daily routines, and cognitive processes[5]. Major Depressive Disorder (MDD) is marked by pervasive emotional dysregulation, cognitive impairment, and a pronounced loss of motivation, significantly disrupting an individual's psychosocial functioning and occupational productivity. The co-occurrence of MDD with substance use disorders, such as opioid dependence, often exacerbates symptom severity and complicates treatment outcomes[6-7].

The capacity of individuals with MDD to engage in social activities, maintain relationships, and function at work is frequently disrupted[8]. The Beck Depression Inventory (BDI) and the Patient Health Questionnaire-9 (PHQ-9) are standardized assessment instruments that healthcare providers employ to accurately diagnose MDD[9]. In the context of co-occurring opioid use disorder and major depressive disorder, standardized assessment instruments such as the PHQ-9 and BDI offer a structured and reliable means to evaluate the intensity and scope of depressive symptoms[10]. These tools not only facilitate early and accurate diagnosis but also inform the development of integrated, patient-centered treatment plans that address both the psychological and substance use dimensions of the disorder[11].

The opioid crisis has had a substantial impact on Kentucky. In 2022, the state reported 2,135 overdose deaths, with opioids accounting for 81.0% of the fatalities. Fentanyl, a synthetic opioid that is highly potent, was implicated in 72.5% of these fatalities. Furthermore, Kentucky has a high incidence of mental health disorders. Approximately 23.77% of adults in Kentucky have experienced a mental illness in the past year, with a substantial proportion of them suffering from severe depressive disorder. Kentucky is a critical region for the research and resolution of these issues due to its high prevalence of opioid-related overdose fatalities and mental health disorders[12]. The impact of these disorders is further exacerbated by the state's distinctive challenges, which include high poverty rates and limited access to healthcare.

The purpose of this case report was to emphasize the efficacy of strategies and interventions that can be implemented in comparable regions that are encountering these dual public health crises by concentrating on Kentucky. The compounded effects on the health and well-being of individuals make it imperative to address the co-occurrence of opioid use disorders and major depressive disorders. Integrated treatment approaches are necessary to effectively manage dual diagnoses, which are characterized by the presence of both a substance use disorder and a mental health disorder[13]. This is of particular significance in Kentucky, where the opioid crisis and mental health issues are prevalent.

The aim of this case report was to conduct a comprehensive case study that explores the relationship between opioid use disorder (OUD) and major depressive disorder (MDD). The study will emphasize the advantages and disadvantages of integrated treatment approaches in enhancing patient outcomes.

Case Presentation

The patient is a 35-year-old male who resides in Louisville, Kentucky. He has a documented history of major depressive disorder (MDD) and opioid use disorder (OUD). His biography encompasses a decade-long battle with substance addiction, predominantly narcotics, and a concurrent diagnosis of depression. The patient's struggle with substance misuse commenced in his early twenties, with prescription narcotics used as a result of a work-related injury. His consumption of heroin and other illicit opioids increased over time. He endured recurrent relapses in spite of numerous rehabilitation endeavors, including inpatient and outpatient programs.

His persistent feelings of melancholy, anhedonia (loss of interest in previously relished activities), and episodes of suicidal ideation have been characterized by his major depressive disorder, which was diagnosed at the same time as his substance use issues. His substance use has frequently been exacerbated by these depressive symptoms, resulting in a pernicious cycle of addiction and mental health deterioration.

The patient manifested severe symptoms of depression upon admission, such as profound melancholy, social withdrawal, and a lack of motivation. In the past year, he revealed that he had experienced numerous non-fatal overdoses as a

result of his daily opioid use. Physical symptoms encompassed indicators of opioid dependence, including tolerance, withdrawal symptoms, and an obsession with the acquisition and utilization of opioids. Significant depressive symptoms, such as insomnia, feelings of worthlessness, and recurrent images of mortality, were identified during his mental health assessment. His capacity to engage in social relationships, maintain employment, and function in daily life was significantly impaired by the combination of these symptoms.

Initial Treatment: The patient was committed to a residential treatment facility that specializes in the treatment of individuals with co-occurring disorders. During the initial phase of treatment, the primary objective was to safely manage withdrawal symptoms and stabilize the patient through detoxification. This phase encompassed medical supervision and support to guarantee that the patient's physical and mental health requirements were satisfactorily addressed during the detoxification process.

Integrated Care Approach: A comprehensive, coordinated treatment plan was designed to address both opioid use disorder and major depressive disorder simultaneously. By combining pharmacologic and psychosocial interventions, the approach aimed to manage physical dependence and alleviate depressive symptoms, promoting sustained recovery and improved overall functioning.

Medication-Assisted Treatment (MAT): Buprenorphine, a medication that alleviates opioid cravings and withdrawal symptoms, was prescribed to the patient.[14] Buprenorphine functions by partially activating opioid receptors in the brain, which alleviates withdrawal symptoms and reduces cravings without generating the same level of euphoria as other opioids.[15] This medication was a component of a more comprehensive approach to the patient's opioid dependence and to facilitate long-term recovery.

Cognitive Behavioral Therapy (CBT): The patient engaged in consistent CBT sessions with the objective of addressing depressive symptoms and establishing effective coping mechanisms[16-17]. CBT is a structured, time-limited therapy that emphasizes the identification and modification of negative thought patterns and behaviors[18]. The patient acquired the ability to manage symptoms of depression, cultivate healthier thought processes, and cultivate the ability to manage stress and substance use triggers through cognitive behavioral therapy (CBT).[19,34]

Group Therapy: The patient participated in group therapy sessions, which offered a supportive environment for the exchange of experiences and the acquisition of insights from peers who were confronted with comparable obstacles. Group therapy is essential for individuals who are rehabilitating from substance use disorders and mental health issues, as it fosters a sense of community and belonging.[20] The patient was also afforded the opportunity to exercise social skills and receive feedback from others during these sessions.

Community Support: The treatment plan incorporated the patient's access to local resources, acknowledging the significance of a robust support network. This necessitated involvement in peer support organizations, which provide continuous accountability and motivation. Furthermore, the patient was enlisted in vocational training programs to enhance their job readiness.[21]

Treatment Outcomes

Short-Term Progress: The patient's drug usage and mental health symptoms significantly improved within the first three months of comprehensive therapy. Regular drug tests that revealed no evidence of opioid usage corroborated his assertion of a discernible decrease in opiate cravings.[22] His attitude, energy levels, and general perspective on life also improved, and his depressed symptoms started to lessen. The patient started to create better coping strategies for stress and emotional control and actively engaged in both individual and group treatment sessions.

Long-term Follow-up: The patient was still showing encouraging results at the six-month mark. He continued to attend regular treatment sessions and was clean, with no relapses noted. Additionally, the patient had obtained a part-time job, which was essential to his recuperation since it gave him a feeling of direction and regularity. He was able to restore his social network and sense of self-worth thanks to this job opportunity, which further aided in his mental health rehabilitation.

The patient said that he felt more optimistic about the future and that he was determined to keep up his sobriety and mental health. His improvement was maintained in large part by regular follow-ups and assistance from local resources.

Discussion

This case highlights numerous substantial obstacles associated with the treatment of individuals who have co-occurring opioid use disorder (OUD) and major depressive disorder (MDD)[23]. The pervasive stigma associated with both mental health issues and substance use disorders is one of the primary barriers[24]. This stigma frequently serves as an impediment to individuals seeking assistance, as they are apprehensive about being judged or discriminated against[25]. Furthermore, there is a significant deficiency in access to integrated care, which involves the concurrent treatment of both conditions. Opioid use is closely linked to increased risk of HIV transmission and exposure to violence, particularly among vulnerable populations such as people who inject drugs and marginalized communities[28]. Opioid use worsens HIV outcomes by weakening immunity, causing microbial dysbiosis, and accelerating liver disease progression, especially with co-infections like hepatitis[29]. Numerous treatment facilities are inadequately outfitted to manage dual diagnoses, which can result in fragmented care that impedes recovery[26]. The treatment process is further complicated by the absence of comprehensive support systems, which include family, community, and healthcare providers[27].

Innovative solutions are essential for surmounting these obstacles. Integrated care models that simultaneously address substance use and mental health issues have demonstrated potential to enhance patient outcomes. These models entail the collaborative efforts of primary care providers, addiction specialists, and mental health professionals to develop a comprehensive treatment plan[30]. Additionally, community-based interventions are essential. Programs that provide accommodation assistance, vocational training, and peer support can offer the requisite support for individuals to sustain their recovery[31]. Policy support is equally critical, as it can facilitate the implementation of integrated care models and guarantee that resources are allocated to support comprehensive treatment programs[32,33].

This case has substantial broader implications. The potential for the application of comparable strategies in other regions with high rates of OUD and MDD is underscored by the success of the integrated treatment approach in this case study[31]. This case bolsters the argument for the widespread adoption of integrated treatment models by illustrating the efficacy of comprehensive, coordinated care. It also emphasizes the necessity of continuous research and policy development to address the intricate requirements of individuals with dual diagnoses. Reducing the burden of opioid addiction and mental health disorders in communities throughout the United States could be achieved by scaling these approaches, which could result in improved outcomes on a significantly larger scale.

In brief, this case study demonstrates the critical significance of integrating care to address both opioid use disorder and major depressive disorder. We can improve the quality of care and support long-term recovery for individuals who are facing these dual challenges by overcoming stigma, increasing access to comprehensive support systems, and implementing innovative solutions[32]. The lessons acquired from this case can be used to inform future endeavors to develop and refine treatment strategies, thereby guaranteeing that a greater number of individuals receive the comprehensive care necessary to achieve and sustain recovery.

The scope of this case report is limited by its emphasis on a singular patient, which may not be indicative of the general population. The generalizability and long-term applicability of the findings are also limited by the relatively brief follow-up period and the reliance on self-reported data.

Conclusion

In summary, this case study illustrates that patients with major depressive disorder and opioid use disorder can experience substantial improvements in their outcomes when they receive integrated treatment. Patients can achieve improved overall health and stability by concurrently treating both conditions through coordinated treatment programs. The results emphasize the necessity of ongoing investment in integrated treatment facilities, expanded access to mental health services, and comprehensive community support programs. In regions such as Kentucky, which are significantly affected by these challenges, these measures are crucial for effectively addressing the interconnected crises of substance addiction and mental health issues. We can improve the quality of care and facilitate long-term recovery for individuals who are confronted with these dual challenges by implementing innovative and comprehensive strategies. To improve the management of co-occurring opioid use disorder (OUD) and major depressive disorder (MDD), it is essential to invest in integrated treatment infrastructures, expand

access to quality mental health care, and strengthen community-based support systems. Additionally, advancing policies that foster holistic care models and prioritizing ongoing research are crucial steps toward addressing the complex needs of individuals with dual diagnoses and developing more effective, evidence-based interventions.

Acknowledgements
None

Conflict of Interest
There is no conflict of interest regarding the publication of this paper.

Financial Disclosure and Funding Sources
This study has been performed without any funding from outside else. The authors received no specific funding for this work.

Contributions to authors: Conception and design, or design of the research, the acquisition, analysis, or interpretation of data, writing—original draft, writing—review & editing were performed by Hasan MR.

Data Availability
Any inquiries regarding supporting data availability of this study should be directed to the corresponding author and are available from the corresponding author on reasonable request. Any questions regarding the availability of the study's supporting data should be addressed to the corresponding author, who can provide it upon justifiable request.

Ethics Approval and Consent to Participate
All methods were carried out in accordance with relevant institutional and ethical guidelines. This study is based on a retrospective review of an anonymized hospital record and did not involve any direct patient interaction or identifiable personal information. As such, the Institutional Review Board (IRB) waived the requirement for ethical approval and informed consent, given the absence of human subject involvement and the use of de-identified data.

Cite this article as: Hasan MR. Exploring the Relationship Between Opioid Use Disorder and Major Depressive Disorder: A Case Study from Kentucky, United States. *J Curr Adv Med Res* 2024;11(1):50-55

ORCID
Md. Rakibul Hasan: https://orcid.org/0000-0002-9152-8753

Article Info
Received: 7 March 2023
Accepted: 3 April 2023
Published: 1 January 2024

References

1. National Academies of Sciences, Medicine, Division of Behavioral, Social Sciences, Board on Behavioral, Sensory Sciences, Committee on the Science of Changing Behavioral Health Social Norms. Ending discrimination against people with mental and substance use disorders: The evidence for stigma change. National Academies Press; 2016 Sep 3
2. Calarco CA, Lobo MK. Depression and substance use disorders: Clinical comorbidity and shared neurobiology. InInternational review of neurobiology 2021;157:245-309
3. Zwick J, Appleseth H, Arndt S. Stigma: how it affects the substance use disorder patient. Substance abuse treatment, prevention, and policy. 2020;15:1-4
4. Committee on Medication-Assisted Treatment for Opioid Use Disorder, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Medications for opioid use disorder save lives. 2019
5. Hasan MR, Rogers W, Egbury G, et al. Exploring Major Mental Health Challenges and Social Stigma Faced by Healthcare Professionals in Clinics and Hospital Facilities in South Asia: A Comprehensive Content Analysis. Int J Adv Multidisc Res Stud 2025; 5(1):274-284
6. Cheetham A, Picco L, Barnett A, Lubman DI, Nielsen S. The impact of stigma on people with opioid use disorder, opioid treatment, and policy. Substance abuse and rehabilitation. 2022:1-2
7. Mitchell AJ, Yadegarfar M, Gill J, Stubbs B. Case finding and screening clinical utility of the Patient Health Questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies. BJPsych open. 2016;2(2):127-38
8. Paykel ES. Basic concepts of depression. Dialogues in clinical neuroscience. 2008;10(3):279-89
9. Center for Substance Abuse Treatment. A guide to substance abuse services for primary care clinicians. 1997
10. Hasan MR, Mason K, Egbury G, et al. Exploring Meta-Cognitive Resilience and Psycho-Social Well-Being Among Bangladeshi University Students During COVID-19: A Mixed-Methods Primary Study of Adaptive Cognitive Strategies. Int J Adv Multidisc Res Stud 2025; 5(1):542-553
11. Priester MA, Browne T, Iachini A, Clone S, DeHart D, Seay KD. Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review. Journal of substance abuse treatment. 2016;61:47-59
12. Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction. 2006;101:76-88
13. Nakao M, Shirotsuki K, Sugaya N. Cognitive–behavioral therapy for management of mental health and stress-related disorders: Recent advances in techniques and technologies. Bio Psycho Social Medicine. 2021;15(1):16
14. Killaspy H, Harvey C, Brasier C, Brophy L, Ennals P, Fletcher J, Hamilton B. Community-based social interventions for people with severe mental illness: a systematic review and narrative synthesis of recent evidence. World Psychiatry. 2022;21(1):96-123
15. Darke S, Farrell M. Which medications are suitable for agonist drug maintenance? Addiction. 2016;111(5):767-74
16. Padwa H, Guerrero EG, Braslow JT, Fenwick KM. Barriers to serving clients with co-occurring disorders in a transformed mental health system. Psychiatric Services. 2015;66(5):547-50
17. Ford JD, Fallot RD, Harris M. Group therapy. In: Treating Complex Traumatic Stress Disorders: An Evidence-Based Guide, 2009
18. Phillips JK, Ford MA, Bonnie RJ, National Academies of Sciences, Engineering, and Medicine, Committee on Pain

Management and Regulatory Strategies to Address Prescription Opioid Abuse. Evidence on strategies for addressing the opioid epidemic. InPain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use 2017 Jul 13. National Academies Press (US)
19. Behera P, Gupta SK, Nongkynrih B, Kant S, Mishra AK, Sharan P. Screening instruments for assessment of depression. Indian Journal of Medical Specialities. 2017;8(1):31-7
20. Thompson K, Barocas JA, Delcher C, Bae J, Hammerslag L, Wang J, et al. The prevalence of opioid use disorder in Kentucky's counties: A two-year multi-sample capture-recapture analysis. Drug and alcohol dependence. 2023; 242:109710
21. Harvey C, Zirnsak TM, Brasier C, Ennals P, Fletcher J, Hamilton B, Killaspy H, McKenzie P, Kennedy H, Brophy L. Community-based models of care facilitating the recovery of people living with persistent and complex mental health needs: a systematic review and narrative synthesis. Frontiers in Psychiatry. 2023;14:1259944
22. Hasan MR. Assessing the Psychosocial Determinants of Mental Health Decline Among Bangladeshi University Students During the COVID-19 Pandemic: A Rapid Systematic Review. Asian Journal of Public Health and Nursing. 2024;1(3):1-14
23. Kabir R, Bai AC, Syed HZ, Hasan MR, Vinnakota D, Kar SK, Singh R, Sathian B, Arafat SY. The effect of COVID-19 on the mental health of the people in the Indian subcontinent: a scoping review. Nepal Journal of Epidemiology. 2023;13(2):1268
24. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. Journal of general internal medicine. 2001;16(9):606-13
25. Hasan MR. Mental Health Challenges in Bangladesh Based on the Integrated Examination of Illicit Drug Use, Substance Abuse, Tobacco Consumption, and Escalating Suicidal Tendencies: A Comprehensive Review. Bangladesh Journal of Infectious Diseases. 2024 Sep 26;11(1):65-70
26. Beck JS. Cognitive behavior therapy: Basics and beyond. Guilford Publications, 2020.
27. Center for Substance Abuse Treatment. Managing chronic pain in adults with or in recovery from substance use disorders. 2012.
28. Kabir R, Vinnakota D, Dehghani L, Sathian B, Padhi BK, Hasan MR. HIV and Violence among Female Sex Workers in India: A Scoping. Women's Health Problems: A Global Perspective. 2024;3-33
29. Hasan MR, Yusuf MA. Microbial Dysbiosis in Diabetic Children with Enteric Hepatitis: The Global Phenomenon and Bangladesh's Contextual Significance. Bangladesh Journal of Infectious Diseases. 2023;10(2):56-8
30. Wiss DA. A biopsychosocial overview of the opioid crisis: considering nutrition and gastrointestinal health. Frontiers in Public Health. 2019;7:193
31. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain physician. 2008;11(2S):S133.
32. McGinty EE, Daumit GL. Integrating mental health and addiction treatment into general medical care: the role of policy. Psychiatric Services. 2020;71(11):1163-9
33. Holton D, White E, McCarty D. Public health policy strategies to address the opioid epidemic. Clinical Pharmacology & Therapeutics. 2018;103(6):959-62
34. Kupferberg A, Bicks L, Hasler G. Social functioning in major depressive disorder. Neuroscience & Biobehavioral Reviews. 2016;69:313-32